Sort   by:  
 Page size 
ProteomicsSpecificity of phosphorylation responses to MAP kinase pathway inhibitors in melanoma cells, experiment 2 of 2
We used phosphoproteomics to compare the responses of the ERK1/2 inhibitors, SCH772984 and GDC0994, and the MKK1/2 inhibitor, trametinib. These are compared with responses to the MKK1/2 inhibitor, selumetinib (AZD6244), previously measured by our lab in the same metastatic melanoma cell line. In thr...
ORGANISM(S): Homo sapiens (Human) 
2018-01-02 | PXD007621 | Pride
Human Melanoma Silac Selumetinib Trametinib Gdc0994 Sch772984 
ProteomicsSpecificity of phosphorylation responses to MAP kinase pathway inhibitors in melanoma cells, experiment 1 of 2
We used phosphoproteomics to compare the responses of the ERK1/2 inhibitors, SCH772984 and GDC0994, and the MKK1/2 inhibitor, trametinib. These are compared with responses to the MKK1/2 inhibitor, selumetinib (AZD6244), previously measured by our lab in the same metastatic melanoma cell line. In thr...
ORGANISM(S): Homo sapiens (Human) 
2018-01-02 | PXD007620 | Pride
Human Melanoma Silac Selumetinib Trametinib Gdc0994 Sch772984 
ProteomicsMIB/MS determines SCH772984 is a selective ERK1/2 inhibitor in pancreatic cancer cells
Mutational activation of the KRAS oncogene is a major genetic driver of pancreatic ductal adenocarcinoma (PDAC) growth. KRAS-dependent PDAC growth is mediated primarily through persistent activation of the RAF-MEK-ERK mitogen-activated protein kinase (MAPK) cascade, one of the most extensively studi...
ORGANISM(S): Homo sapiens (Human) 
2024-05-29 | PXD043585 | Pride
Erk Mib/ms Kinases Pancreatic cancer 
UnknownCucurbitacin B and SCH772984 exhibit synergistic anti-pancreatic cancer activities by suppressing EGFR, PI3K/Akt/mTOR, STAT3 and ERK signaling.
Not available
S-EPMC5732720 | biostudies-literature
TranscriptomicsSelective extracellular signSelective Extracellular Signal-Regulated Kinase 1/2 (ERK1/2) Inhibition by the SCH772984 Compound Attenuates In Vitro and In Vivo Inflammatory Responses and Prolongs Survival in Murine Sepsis Models
Sepsis is the leading cause of death in intensive care units worldwide. Current treatments of sepsis are largely supportive and clinical trials using specific pharmacotherapy for sepsis have failed to improve outcomes. Here, we used the lipopolysaccharide (LPS)-stimulated mouse RAW264.7 cell line an...
ORGANISM(S): Mus musculus 
2021-09-24 | GSE179554 | GEO
UnknownSelective Extracellular Signal-Regulated Kinase 1/2 (ERK1/2) Inhibition by the SCH772984 Compound Attenuates In Vitro and In Vivo Inflammatory Responses and Prolongs Survival in Murine Sepsis Models.
Not available
S-EPMC8508766 | biostudies-literature
TranscriptomicsSmall molecule inhibition of ERK dimerization prevents tumorigenesis by Ras-ERK pathway oncogenes
About 50% of human malignancies exhibit unregulated signalling through the Ras-ERK1/2 (ERK) pathway, as a consequence of activating mutations in members of Ras and Raf families. However, the quest for alternative Ras-ERK pathway-directed therapies is desirable. Upon phosphorylation ERK dimerize. We ...
ORGANISM(S): Homo sapiens 
2015-04-24 | E-GEOD-68230 | biostudies-arrayexpress
GenomicsSelective Extracellular Signal-Regulated Kinase 1/2 (ERK1/2) Inhibition by the SCH772984 Compound Attenuates In Vitro and In Vivo Inflammatory Responses and Prolongs Survival in Murine Sepsis Models
This is an accompanying ATAC-seq data to the transcriptomic survey of RAW264.7 cells treated with ERK1/2 inhibitor SCH772984 upon 1hr, 4hrs and 24 hrs LPS challenge. The transcriptomic data are deposited in GEO under GSE179554.
ORGANISM(S): Mus musculus 
2021-09-24 | GSE180085 | GEO
GenomicsRNA sequencing of rhabdomyosarcoma RD cells transfected with NRAS siRNAs for 48 h or treated with 300nM ERKi SCH772984 for 24 h
RNA sequencing of rhabdomyosarcoma RD cells transfected with NRAS siRNAs for 48 h or treated with 300nM ERKi SCH772984 for 24 h
PRJNA746601 | ENA
GenomicsSelective extracellular signSelective Extracellular Signal-Regulated Kinase 1/2 (ERK1/2) Inhibition by the SCH772984 Compound Attenuates In Vitro and In Vivo Inflammatory Responses and Prolongs Survival in Murine Sepsis Models
Selective extracellular signSelective Extracellular Signal-Regulated Kinase 1/2 (ERK1/2) Inhibition by the SCH772984 Compound Attenuates In Vitro and In Vivo Inflammatory Responses and Prolongs Survival in Murine Sepsis Models
PRJNA744191 | ENA
Sort   by:  
 Page size